This study aims to evaluate the antimicrobial effectiveness of inter-appointment intracanal medicament with either CH alone (Calcipex) or CH with iodoform (Metapex) for the treatment of infected root canals of teeth diagnosed with chronic apical periodontitis.
And, to compare the effectiveness of rotary master apical file with ultrasonic activation of endodontic file in the removal of oil based intracanal medicament from the canal.
Risk / Benefit Assessment At this point investigators are not anticipating any risk related to the trial intervention.
TRIAL DESIGN: Two-arm parallel design, Randomized controlled trial. SETTING: Dental Clinics, Aga Khan University Hospital, Karachi
EXPECTED DURATION OF TRIAL:
Study Duration: Four months after registration By visit: 2 visits, with followup period of 7 days±3 after the first visit.
CRITERIA FOR EVALUATION Primary Efficacy Endpoint Reduction in microbial load (CFU/ml) at 7 days after use of intracanal medicament Safety Evaluations No Incidence of adverse events with any agent
Investigational product management: The investigator will purchase the drug locally and will label and store in safe and secure place. The product can be stored at room temperature i.e.1-30℃
Sampling technique: Non probability purposive sampling Sampling size: Sample size was calculated using WHO sample size calculator. Dutta et al.16 showed that the population mean and SD of teeth treated with calcium hydroxide based intracanal medicaments were 50.3±13 CFU/mL. Keeping the absolute precision at 0.05 and level of confidence at 95%, the required sample size turned out to be 26 teeth. The sample is inflated to 30. As tthere are two groups, therefore, a total of 60 teeth will be taken.
RANDOMIZATION, BLINDING AND TREATMENT ALLOCATION:
The selected subjects will be assigned to one of the two study groups only known to the researcher who is not involved in the outcome assessment using block randomization. This would be facilitated by CTU. The block size would be 6.
Group A (Control group) - Calcipex group (n = 30) Group B (Intervention group) - Metapex group (n = 30) The sample in eppendorff tubes will be sent in a zip lock bag to the microbiology laboratory labeled with either group A or B. Patient, analyzer and the statistician will be blinded about the intervention groups. The recruitment of patients, collection of samples and placement of intracanal medicament will be performed by a single investigator.
POSSIBLE RISKS OR BENEFITS:
There is no risk involved in this study as the study is based on routine procedure of endodontic treatment. It will be a benefit for future patients which will help us to decide which intracanal medicament is more effective to use in infected canals.
DATA COLLECTION INSTRUMENTS The data will be collected on case report form (CRF) on first and second visit. The CRF has been developed by investigator and reviewed by experts of the field. Data will be stored in a password protected database. To assure quality, data will be double checked to avoid discrepancies and errors.
PATIENT CONFIDENTIALITY, ACCESS AND STORAGE:
The information provided by the participant will remain confidential. Nobody except investigators will have access to it. Participants' name and identity will not be disclosed at any time. However, the data may be seen by ethical review committee, DSMB or any local regulatory body. As per GCP and other guidelines, data will be retained for 3 years.
ETHICAL CONSIDERATIONS:
The study will be started after obtaining approval from Institutional Ethics Review Committee(approved already). Patients who fulfilled the inclusion criteria will receive detailed information regarding the study and only those participants will be recruited who will sign the written consent form. The study will be conducted according to the World Medical Association's Declaration of Helsinki and the principles of GCP (Good Clinical Practice). Any subsequent protocol amendments will be submitted to ERC and regulatory authorities for approval. The trial will be conducted in compliance with regulations, particularly specifying pharmaco-vigilance reporting and a copy of final study report will be submitted to ERC.
DATA COLLECTION PROCEDURE:
First visit: The tooth diagnosed with chronic apical periodontitis will be anesthetized using 2% lidocaine (with 1:100,000 epinephrine) and isolated with the rubber dam. Access opening will be performed using high and low speed round bur. Coronal and radicular necrotic pulp will be extirpated using barbed broaches. The root canal will be initially prepared by using hand K-files (Endoflex; K-File, Size 8-20, NiTi) with quarter turn and pull motion. A 23-gauge side vented needle will be used to deliver 1 mL of sodium hypochlorite for irrigation after each instrument size. The working length will be established with an apex locator and confirmed by the periapical radiographs. Chemo-mechanical preparation will be completed using Protaper Next (Dentsply; Sirona, USA) depending on both root anatomy and initial diameter of the root canal. The preparation will be completed in the same appointment in all cases. After completion of the preparation, the canals will be irrigated with saline and dried with paper points. A sterile paper point (size 20; EZ Endo, USA) will be inserted to the confirmed working length of the canal, and retained in position for 60 seconds for sampling (S1). Afterwards, the paperpoint will be gently removed and placed in an eppendorf tube (5 ml) containing Brain Heart Infusion Broth and sent directly to the microbiology laboratory for microbial cultivation.
In Group A, the canal will be medicated with Calcipex (Calcipex®II, Nishika, Yamaguchi, Japan) which will be placed by means of lentulo spiral fillers and packed with a cotton pellet at the level of canal entrance. Access cavity will be filled with a temporary filling, Cavit-G (3M-ESPE, USA). In Group B, the canal will be medicated with Metapex (Meta Biomed, Korea) using the same protocol as mentioned above.
Second visit: Patient will be followed up on seven +/- 3 days, the tooth will be isolated and the protocol will be followed the same way as described before. The temporary filling will be removed and the paste carried out of the canal by using sterile file and irrigated with normal saline to wash out the medicament. A post medication sample will be taken with the help of sterile paper point in both groups as described previously (S2). The canals will be then obturated with gutta-percha and calcium hydroxide sealer (Sealapex, Kerr Dental, USA) by lateral compaction technique. A definitive restoration will be placed subsequently.
Outcome assessment: It will be done in the microbiology laboratory on the basis of CFU/ml.
RIGHT OF REFUSAL TO PARTICIPATE AND WITHDRAWAL:
Participants will be given choice to either participate or refuse to participate in the study
INCENTIVE:
No incentive will be given to the patient.
